Golgi Phosphoprotein 3 Represents a Novel Tumor Marker for Gastric and Colorectal Cancers

Table 2

Differences in serum GOLPH3 concentration based on clinical characteristics of GC and CRC.

	Gastric cancer			Colorectal cancer
	No.	Median (IQR25-75)	value	No.	Median (IQR25-75)	value
Sex			0.729			0.120
Male	56	6.34 (5.59-7.98)		66	6.81 (4.33-12.87)
Female	46	6.80 (5.90-7.67)		70	7.95 (6.26-12.75)
Age			0.232			0.058
<60	36	6.33 (5.59-7.17)		46	6.40 (4.36-11.87)
≥60	66	6.78 (5.57-8.13)		90	7.82 (6.25-13.12)
Tumor size			0.000			0.000
<5 cm	70	6.32 (5.49-6.90)		58	6.80 (4.36-8.63)
≥5 cm	32	7.98 (6.54-14.54)		78	9.07 (6.25-13.77)
Differentiation			0.001			0.000
G1-G2	78	6.35 (5.49-7.14)		110	7.09 (4.58-11.24)
G3	24	8.63 (6.19-16.86)		26	13.54 (7.84-14.93)
T stage			0.017			0.001
T1-T2	29	6.35 (3.67-6.89)		27	5.86 (3.25-8.39)
T3-T4	73	6.69 (5.81-8.79)		109	7.96 (6.23-13.06)
N stage			0.000			0.000
Negative	16	5.12 (2.58-6.20)		71	7.04 (4.59-8.75)
Positive	86	6.81 (6.06-8.21)		65	9.56 (6.25-14.78)
M stage			0.001			0.001
M0	97	6.38 (5.42-7.41)		128	7.38 (5.45-11.93)
M1	5	17.18 (14.13-22.75)		8	14.47 (10.02-19.55)